Carl N Kraus

Summary

Publications

  1. ncbi request reprint Clinical implications of patient-provider agreements in opioid prescribing
    Carl N Kraus
    Nanotherapeutics, Inc, 13859 Progress Blvd, Suite 300 Alachua FL 32615, USA
    Curr Drug Saf 10:159-64. 2015
  2. pmc Ambush of Clostridium difficile spores by ramoplanin: activity in an in vitro model
    Carl N Kraus
    Nanotherapeutics, Inc, Alachua, Florida, USA
    Antimicrob Agents Chemother 59:2525-30. 2015
  3. ncbi request reprint Improving the effect of FDA-mandated drug safety alerts with Internet-based continuing medical education
    Carl N Kraus
    Nanotherapeutics Inc, Alachua, FL 32615, USA
    Curr Drug Saf 8:11-6. 2013
  4. ncbi request reprint The practicing clinician and regulatory safety concerns
    R G McAllister
    DrugCite Inc, USA
    Curr Drug Saf 8:17-24. 2013
  5. doi request reprint The safety record of fusidic acid in non-US markets: a focus on skin infections
    Carl N Kraus
    Infectious Diseases, Nanotherapeutics, Inc, Alachua, Florida 32615, USA
    Clin Infect Dis 52:S527-37. 2011

Collaborators

  • R G McAllister
  • TIMOTHY FRANSON

Detail Information

Publications5

  1. ncbi request reprint Clinical implications of patient-provider agreements in opioid prescribing
    Carl N Kraus
    Nanotherapeutics, Inc, 13859 Progress Blvd, Suite 300 Alachua FL 32615, USA
    Curr Drug Saf 10:159-64. 2015
    ..Based on our survey, clinicians consider the PPA of potential value, but data regarding the utility of such an instrument are lacking...
  2. pmc Ambush of Clostridium difficile spores by ramoplanin: activity in an in vitro model
    Carl N Kraus
    Nanotherapeutics, Inc, Alachua, Florida, USA
    Antimicrob Agents Chemother 59:2525-30. 2015
    ..This action, in conjunction with its already established bactericidal activity against vegetative C. difficile forms, supports further evaluation of ramoplanin for the prevention of relapse after C. difficile infection in patients. ..
  3. ncbi request reprint Improving the effect of FDA-mandated drug safety alerts with Internet-based continuing medical education
    Carl N Kraus
    Nanotherapeutics Inc, Alachua, FL 32615, USA
    Curr Drug Saf 8:11-6. 2013
    ..These results demonstrate that improvement in understanding of specific drug toxicities is enhanced by a CME intervention...
  4. ncbi request reprint The practicing clinician and regulatory safety concerns
    R G McAllister
    DrugCite Inc, USA
    Curr Drug Saf 8:17-24. 2013
    ..Current efforts to assess the effectiveness of regulatory efforts at risk communications should lead to changes in the approaches used and, ultimately, improvement in the safe use of both new and established drugs...
  5. doi request reprint The safety record of fusidic acid in non-US markets: a focus on skin infections
    Carl N Kraus
    Infectious Diseases, Nanotherapeutics, Inc, Alachua, Florida 32615, USA
    Clin Infect Dis 52:S527-37. 2011
    ....